氟哌噻吨美利曲辛联合帕罗西汀对重度抑郁障碍患者躯体化症状、睡眠和认知功能的影响分析

doi:10.3969/j.issn.1000-8535.2024.07.008

摘要/Abstract

摘要： 目的探讨氟哌噻吨美利曲辛联合帕罗西汀对重度抑郁障碍（MDD）患者躯体化症状、睡眠和认知功能的影响分析以及临床应用效果。方法回顾性分析2020年8月—2023年2月在南昌市某医院接受治疗的120例MDD患者相关资料,按照其治疗方案不同分为帕罗西汀治疗组（常规组,n=55）和氟哌噻吨美利曲辛联合帕罗西汀治疗组（联合组,n=65）。两组患者治疗周期均为4周,比较两组患者治疗前和治疗第2、4周的汉密尔顿抑郁量表（HAMD-17）评分、躯体化症状自评量表（SSS）评分、睡眠质量评分（PSQI）、神经心理状态评定量表（RBANS）;且治疗后对患者进行1个月的随访比较两组患者治疗后总体疗效及不良反应发生情况。结果经治疗第2、4周联合组RBANS评分高于常规组（P<0.05）,而PSQI评分、SSS评分、HAMD-17评分均低于常规组（P<0.05）。治疗后1个月随访资料显示,两组患者不良反应总发生率比较,差异无统计学意义（P>0.05）,且总有效率高于常规组（P<0.05）。结论氟哌噻吨美利曲辛联合帕罗西汀对MDD患者临床应用疗效确切,还可以帮助患者减轻躯体化症状,改善患者睡眠质量,并且提高患者认知功能。

关键词: 氟哌噻吨美利曲辛, 帕罗西汀, 联合用药, 重度抑郁症, 躯体化症状, 睡眠, 认知功能

Abstract: Objective To investigate the effect of haloperitoxine melitraxine combined with paroxetine on somatic symptoms,sleep and cognitive function in patients with major depressive disorder（MDD）and its clinical application effects．Methods A retrospective analysis was performed on the relevant data of 120 patients with MDD who received treatment in our hospital from August 2020 to February 2023,and divided into conventional group（treated with paroxetine,55 cases）and combined group（haloperitoxetex melitraxine combined with paroxetine,65 cases）according to their different treatment regimens．The treatment duration of the two groups was 4 weeks,and the Hamilton Rating Scale for Depression（HAMD-17）score,Somatized Symptom Self-rating Scale（SSS）score,Sleep Quality Score（PSQI） and Neuropsychological State Rating Scale（RBANS）scores were compared before treatment and at the 2nd and 4th week of treatment．After treatment,the patients were followed up for 1 month,and the total efficacy and adverse reactions of the two groups of patients after treatment were compared．Results After 2 and 4 weeks of treatment,the combined group showed significantly higher RBANS scores compared to the control group（P<0.05）,while PSQI scores,SSS scores and HAMD-17 scores were significantly lower in the combined group compared to the control group（P<0.05）．One month after treatment,follow-up data showed that there was no statistically significant difference in the overall incidence of adverse reactions between the two groups（P>0.05）．Additionally,the total effective rate was significantly higher in the combined group compared to the control group（P<0.05）．Conclusions Haloperitoxine melitrexine combined with paroxetine has a definite clinical effect in patients with MDD,and can also help patients reduce somatization symptoms,improve patients' sleep quality,and improve patients' cognitive function．

Key words: haloperithioxine melitraxine, paroxetine, combination medications, major depressive disorder, somatization symptoms, sleep, cognitive function

刘晓燕, 谭美玉, 郭洋达, 陈腊梅. 氟哌噻吨美利曲辛联合帕罗西汀对重度抑郁障碍患者躯体化症状、睡眠和认知功能的影响分析[J]. 广州医药, 2024, 55(7): 747-751.

LIU Xiaoyan, TAN Meiyu, GUO Yangda, CHEN Lamei. Analysis of the effect of haloperitoxine melitrexine in combination with paroxetine on somatic symptoms,sleep and cognitive function in patients with major depressive disorder[J]. Guangzhou Medical Journal, 2024, 55(7): 747-751.

参考文献

[1] 化振,杨来启,吴兴曲,等.重度抑郁症患者心理弹性及相关因素的研究[J].解放军预防医学杂志,2021,39(1):16-18.
[2] 聂玲,姜青春,张英.抑郁症患者的护理干预实践及效果分析[J].心理月刊,2023,18(12):135-137.
[3] 皮开琼,陶建英.健康教育对抑郁症患者陪护家属认知水平的影响[J].中国现代药物应用,2013,7(15):233-235.
[4] 鲁玉荣,聂智勇,陈钰.帕罗西汀联合音乐放松疗法对抑郁症病人心理及睡眠状态的影响[J].护理研究,2020,34(20):3625-3628.
[5] 王家艳,林晓伟,许玉皎.滋水清肝饮加减联合氟哌噻吨美利曲辛对肾虚肝郁证老年脑梗死抑郁症患者的疗效及炎症因子和HPA轴的影响[J].中国老年学杂志,2020,40(15):3255-3258.
[6] 杨光,李可法,梁建军.氟哌噻吨美利曲辛片联合盐酸帕罗西汀治疗老年脑卒中后抑郁的效果及对神经功能的影响[J].黑龙江医学,2023,47(22):2739-2741.
[7] 卫生部卫生统计信息中心,北京协和医院世界卫生组织疾病分类合作中心.国际疾病分类(ICD-10)应用指导手册[M].北京:中国协和医科大学出版社,2001:67-69.
[8] UVAIS N A,NALAKATH M J.Prevalence of psychological morbidities among hospital staff during the second wave of COVID-19 in India[J].Prim Care Companion CNS Disord,2023,25(5):22m03469.
[9] SHI L,LU Z A,QUE J Y,et al.Prevalence of and risk factors associated with mental health symptoms among the general population in China during the coronavirus disease 2019 pandemic[J].JAMA Netw Open,2020,3(7):e2014053.
[10] 马欢. 父本剥夺对共情水平的影响及催产素系统参与机制[D].西安:陕西师范大学,2021.
[11] 周晶晶,王小平,方贻儒,等.精神科医生对伴有自杀意念和自杀未遂抑郁症患者的诊疗现况调查[J].神经疾病与精神卫生,2023,23(9):626-634.
[12] 张易,郑素珍,杨丽薇,等.中度有氧运动对老年抑郁症病人5-羟色胺、去甲肾上腺素水平及自主神经功能的干预效果研究[J].实用老年医学,2023,37(6):595-598.
[13] 胡孟谋,张霞军,欧阳和中.血清5-HT、IL-6水平预测阿尔茨海默病患者伴发抑郁症的研究[J].新医学,2023,54(1):35-39.
[14] YAMADA R,WADA A,STICKLEY A,et al.Augmentation therapy with serotonin1A receptor partial agonists on neurocognitive function in schizophrenia:A systematic review and meta-analysis[J].Schizophr Res Cogn,2023(34):100290.
[15] 马丽景,杨赞琦,张佳,等.度洛西汀联合重复经颅磁刺激对重度抑郁症患者神经递质及认知功能的影响[J].中国康复,2023,38(5):296-299.
[16] 刘海峰. 氟哌噻吨美利曲辛联合帕罗西汀治疗脑卒中后重性抑郁障碍的临床效果[J].临床医学,2018,38(2):106-107.
[17] 许珂,沈晓旭,周书喆,等.中医定向透药物疗法联合抗抑郁药对抑郁症患者的临床疗效研究[J].中国临床药理学杂志,2023,39(16):2330-2333.
[18] 白由竹. 西酞普兰联合阿立哌唑治疗中度至重度抑郁症的疗效及安全性研究[J].中国药物评价,2021,38(5):441-444.